|
Strategy
|
Drug
|
N
|
IC
|
IC025
|
IC975
|
ROR
|
ROR025
|
ROR975
|
|---|
|
Total
|
Total ICIs
|
6260
|
2.53
|
2.49
|
2.57
|
6.14
|
5.99
|
6.30
|
|
Monotherapy
|
Anti-PD-1
|
3398
|
2.26
|
2.20
|
2.31
|
4.99
|
4.82
|
5.16
|
|
Nivolumab
|
2219
|
2.24
|
2.17
|
2.31
|
4.90
|
4.70
|
5.12
|
|
Pembrolizumab
|
1175
|
2.29
|
2.19
|
2.39
|
5.07
|
4.78
|
5.38
|
|
Cemiplimab
|
4
|
1.60
|
−0.31
|
3.50
|
3.07
|
1.13
|
8.32
|
|
Anti-PD-L1
|
269
|
1.68
|
1.48
|
1.88
|
3.26
|
2.89
|
3.68
|
|
Atezolizumab
|
175
|
1.54
|
1.29
|
1.79
|
2.95
|
2.54
|
3.43
|
|
Avelumab
|
27
|
1.66
|
1.01
|
2.31
|
3.22
|
2.20
|
4.73
|
|
Durvalumab
|
67
|
2.07
|
1.66
|
2.47
|
4.31
|
3.37
|
5.49
|
|
Anti-CTLA-4
|
708
|
2.97
|
2.84
|
3.09
|
8.29
|
7.68
|
8.95
|
|
Ipilimumab
|
706
|
2.97
|
2.84
|
3.09
|
8.30
|
7.69
|
8.96
|
|
Tremelimumab
|
2
|
1.55
|
−1.49
|
4.59
|
2.98
|
0.72
|
12.33
|
|
Anti-CTLA-4 vs anti-PD-1
| |
708
| | | |
1.68
|
1.55
|
1.83
|
|
Anti-CTLA-4 vs anti-PD-L1
| |
708
| | | |
2.54
|
2.20
|
2.93
|
|
Polytherapy
|
Polytherapy1
|
64
|
4.41
|
4.00
|
4.83
|
25.60
|
19.44
|
33.71
|
|
Polytherapy2
|
1664
|
3.15
|
3.07
|
3.24
|
9.58
|
9.11
|
10.07
|
|
Polytherapy3
|
109
|
4.05
|
3.73
|
4.36
|
18.93
|
15.45
|
23.20
|
|
Polytherapy4
|
27
|
3.96
|
3.31
|
4.61
|
17.68
|
11.67
|
26.78
|
|
Polytherapy vs. Monotherapy
| |
1864
| | | |
2.00
|
1.89
|
2.11
|
- *In Table 2, bold text denotes significant signals. Polytherapy1: Nivolumab+ pembrolizumab+ ipilimumab; Polytherapy2: Nivolumab+ ipilimumab; Polytherapy3: Pembrolizumab+ ipilimumab; Polytherapy4: Durvalumab+ tremelimumab. N: number of records; IC025: the lower end of the 95% confidence interval of IC. IC975: the upper end of the 95% confidence interval of IC. ROR025: the lower end of the 95% confidence interval of ROR. ROR975: the upper end of the 95% confidence interval of IC
